Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

AIM: To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model. METHODS: Sixteen corneas of 16 rats were chemically cauterized and randomized into four groups: bevacizumab grou...

Full description

Saved in:
Bibliographic Details
Published in:International journal of ophthalmology Vol. 6; no. 2; pp. 136 - 140
Main Author: Ebru Eren Akar Veysi ner Cem Küükerdnmez Yonca Aydin Akova
Format: Journal Article
Language:English
Published: China International Journal of Ophthalmology Press 2013
Press of International Journal of Ophthalmology (IJO PRESS)
Subjects:
Basic Research
bevacizumab
corneal
corneal neovascularization
injection
neovascularization
pegaptanib
ranibizumab
subconjunctival
subconjunctival injection
bevacizumab
pegaptanib
subconjunctival injection
ranibizumab
corneal neovascularization
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AIM: To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model. METHODS: Sixteen corneas of 16 rats were chemically cauterized and randomized into four groups: bevacizumab group that treated with 0.05mL/1.25mg bevacizumab, ranibizumab group that treated with 0.05mL/0.5mg ranibizumab, pegaptanib group that treated with 0.05mL/0.15mg pegaptanib sodium, and control group that treated with 0.05mL saline solution. Digital photographs of the corneas were taken and analyzed using an image analysis software program. All corneas were excised and examined histologically on the 15 th day. RESULTS: Each treatment group had significantly less neovascularized corneal areas and fewer blood vessels than the control group (all P <0.05). In addition, bevacizumab group had significantly less neovascu-larized corneal areas and fewer blood vessels than ranibizumab and pegaptanib groups (both P <0.05). However, there was no significant difference between the ranibizumab and pegaptanib groups regarding percentage of neovascularized corneal areas and number of blood vessels (both P >0.05). CONCLUSION: Subconjunctival bevacizumab, ranibiz-umab, and pegaptanib sodium were effective with no corneal epitheliopathy for inhibiting corneal neovascularization after corneal burn in rats .Bevacizumab was more effective than ranibizumab and pegaptanib sodium.
Bibliography:Ebru Eren Akar 1 , Veysi ner 2 , Cem Küükerdnmez 3 , Yonca Aydin Akova 41 Department of Ophthalmology, Artvin State Hospital, Artvin, Turkey 2 Department of Ophthalmology, Recep Tayyip Erdogan University Medical School, Rize, Turkey 3 Department of Ophthalmology, Izmir University Medical School, Izmir, Turkey 4 Kavaklidere Bayindir Hospital, Ankara, Turkey
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2222-3959
2227-4898
DOI:10.3980/j.issn.2222-3959.2013.02.05